MedTrace Logo

Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis

NCT01178372 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2010-08-10

No results posted yet for this study

Summary

Hepatic encephalopathy (HE), a challenging complication of advanced liver disease, occurs in approximately 30-45% of patients with cirrhosis. The treatment of choice is non-absorbable disaccharides, such as lactulose and lactitol.Probiotics are effective in the treatment of minimal hepatic encephalopathy which precipitates hepatic encephalopathy. The investigators will assess the effects of lactulose and probiotics for the prevention of recurrence of HE (secondary prophylaxis) in patients after the recovery of an episode of overt hepatic encephalopathy.

Conditions

  • Hepatic Encephalopathy

Interventions

DRUG

Lactulose

will receive 30-60 ml of lactulose in 2 or 3 divided doses so that patient passed 2-3 semisoft stools per day

DRUG

Probiotics(VSL#3)

will receive VSL#3 (110 billion CFU)three times a day

Sponsors & Collaborators

  • Govind Ballabh Pant Hospital

    lead OTHER_GOV

Principal Investigators

  • Barjesh C Sharma, MD,DM · G B Pant Hospital New Delhi 110002

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Completion
2010-09-30

Countries

  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01178372 on ClinicalTrials.gov